Angela Foster
Family · Mayflower, ARNPI 1174847313
Payments from drug & device makers
Across 296 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$904
- AstraZeneca$833
- Pfizer$553
- Novo Nordisk$311
- Amgen$306
- Lilly USA, LLC$303
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 67 | $904 |
| AstraZeneca | 22 | $833 |
| Pfizer | 35 | $553 |
| Novo Nordisk | 14 | $311 |
| Amgen | 17 | $306 |
| Lilly USA, LLC | 23 | $303 |
| GSK | 13 | $240 |
| Otsuka America Pharmaceutical, Inc. | 9 | $156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $152 |
| Astellas Pharma US Inc | 9 | $146 |
| Lundbeck LLC | 7 | $138 |
| Phathom Pharmaceuticals, Inc. | 7 | $124 |
| Novartis | 7 | $111 |
| Sumitomo Pharma America, Inc. | 8 | $107 |
| Phadia US Inc. | 2 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $95 |
| Abiomed | 4 | $85 |
| Johnson & Johnson | 4 | $77 |
| Sunovion Pharmaceuticals Inc. | 5 | $74 |
| Shield Therapeutics Inc | 4 | $69 |
| Biohaven Pharmaceuticals, Inc. | 2 | $56 |
| Upsher-smith Laboratories LLC | 3 | $55 |
| Exact Sciences | 3 | $46 |
| Dexcom, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Merck | 2 | $33 |
| Gilead | 2 | $31 |
| Bayer | 1 | $27 |
| Boehringer Ingelheim | 2 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,453 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $103,880 |
| JardianceEmpagliflozin | 111 | $95,949 |
| MounjaroTirzepatide | 51 | $57,273 |
| EliquisApixaban | 57 | $49,396 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,465 |
| LinzessLinaclotide | 49 | $27,508 |
| JanuviaSitagliptin Phosphate | 20 | $22,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $20,715 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,882 |
| XareltoRivaroxaban | 18 | $17,858 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $17,152 |
| FarxigaDapagliflozin Propanediol | 17 | $15,860 |
| TradjentaLinagliptin | 11 | $9,818 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,659 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $26 | $105,767122 claims |
| Novo NordiskOzempic | $311 | $103,880103 claims |
| Lilly USA, LLCMounjaro | $303 | $57,27351 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $77 | $56,32429 claims |
| PfizerEliquis | $553 | $49,39657 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $240 | $47,52682 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $833 | $38,48159 claims |
| AbbVieLinzess | $904 | $27,50849 claims |
| MerckJanuvia | $33 | $22,64720 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $7,60313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Mayflower
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.